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coronary CTA for in-scaffold minimal lumen area assess-
ment, with OCT as a reference. Among the 101 patients 
of the ABSORB Cohort B trial, 35 underwent both OCT 
and coronary CTA. The feasibility of quantitative evalu-
ation was 74%. In the scaffolded segment, coronary CTA 
underestimated minimal lumen area by 9.8% (accuracy 
0.39  mm2, precision 1.0  mm2, 95% limits of agreement 
−1.71 to 2.50 mm2). A similar level of agreement was 
observed in the non-scaffolded segment. Compared to 
OCT, coronary CTA appears to be accurate for the estima-
tion of in-scaffold luminal areas, with no difference com-
pared to the non-scaffolded region.
Keywords Coronary computed tomography 
angiography · Polymeric scaffolds · Optical coherence 
tomography
Abbreviations
BVS  Bioresobable vascular scaffold
CTA  Computed tomography angiography
IVUS  Intravascular ultrasound
FFRCT  Fractional flow reserve derived from computed 
tomography
OCT  Optical coherence tomography
PCI  Percutaneous coronary interventions
PLLA  Poly-l-lactide
Introduction
The field of interventional cardiology has been revolution-
ized by the introduction of the Absorb bioresorbable vascu-
lar scaffolds (Absorb BVS, Abbott Vascular, Santa Clara, 
CA). The restoration of the vascular integrity of the ves-
sel might supersede the long-term limitations seen with 
Abstract To establish the accuracy of coronary computed 
tomography angiography (CTA) for in-scaffold quantita-
tive evaluation with optical coherence tomography (OCT) 
as a reference. The translucent backbone of the bioresorb-
able scaffold allow us to evaluate non-invasively the coro-
nary lumen with coronary CTA. In the ABSORB first-in-
man studies, coronary CTA was shown to be feasible for 
quantitative luminal assessment. Nevertheless, a compari-
son with an intravascular modality with higher resolution 
has never been performed. In the ABSORB Cohort B trial, 
101 patient with non-complex lesions were treated with the 
fully biodegradable vascular scaffold. For this analysis, all 
patients who underwent coronary CTA at 18 months and 
OCT within ±180 days were included. Coronary CTA and 
OCT data were analysed at an independent core labora-
tory for quantitative cross-sectional luminal dimensions. 
The primary objective was the accuracy and precision of 
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permanent metallic stents [1]. At mid-term follow-up, 
randomised trials have shown comparable clinical results 
between bioresorbable vascular scaffolds (BVS) and cobalt-
chromium everolimus-eluting stent for the treatment of 
non-complex coronary lesions [2, 3]. Also, the translucent 
backbone of the BVS allows for the non-invasive investi-
gation of the coronary lumen with coronary CTA, thereby 
overcoming the limitations observed in patients previously 
revascularized with metallic stents [4].
In the ABSORB first-in-man trials (Cohort A and B), 
serial coronary CTA was performed. In these studies, high 
feasibility for quantitative in-scaffold luminal assessment 
was reported. In addition, the functional component of 
the treated region was assessed using computational fluid 
dynamics. Fractional flow reserve derived from coronary 
CTA (i.e., FFRCT) was serially assessed. The persistence of 
FFRCT normalization at long-term follow-up was observed 
[4]. The accuracy and precision of luminal geometry seg-
mentation are of paramount importance for both quantita-
tive luminal analysis and FFRCT computation.
Over the past two decades, major advances have been 
introduced in the field of computed tomography (i.e., the 
advent of 256 and 320-detectors scanners, dual-source 
CT, iterative algorithm for reconstructions, etc). With the 
best-in-class CT scanners available, the spatial resolution 
has been reported in the range of 250 microns. In contrast, 
invasive optical coherence tomography (OCT) has a resolu-
tion of 10–20 microns and is widely recognized as a gold 
standard for coronary luminal measurements [5]. Never-
theless, a comparison of in-scaffold luminal areas between 
coronary CTA and an intravascular modality with higher 
resolution have never been performed.
Therefore, the aim of this study was: (1) To assess the 
accuracy of coronary CTA for in-scaffold quantitative lumi-
nal analysis at mid-term follow-up with OCT as a reference 
and; (2) To validate the coronary CTA-derived luminal area 
measurement at the level of the radiopaque marker.
Methods
Study design
In the ABSORB B (ABSORB Clinical Investigation 
Cohort B, Everolimus Eluting Coronary Stent System 
Clinical Investigation) trial, one hundred and one patients 
with non-complex de novo coronary lesion were enrolled 
at 12 centres between March and November 2009. 
Informed consent was obtained from all individual partic-
ipants included in the study. The details of the trial have 
been previously described elsewhere [6]. Seventy-one 
patients underwent coronary CTA at 18 months with the 
use of at least a 64-detector (or higher) CT scanner [7]. In 
addition, patients were divided into two groups (B1 and 
B2) for serial invasive imaging (e.g., angiography, intra-
vascular ultrasound and OCT) at different time points [6]. 
OCT was performed at 12 or 24-month follow-up in 28 
and 31 patients in cohort B1 and B2, respectively [8]. All 
patients with coronary CTA and OCT evaluations were 
included in the present analysis (Fig. 1).
Study device and procedure
The BVS balloon-expandable device consists of a poly-
mer backbone of poly-l-lactide (PLLA) coated with a 
thin layer of a 1:1 mixture of poly(l-lactide-co-d, l-lac-
tide) (PDLLA) polymer and the antiproliferative drug 
everolimus containing 100  μg everolimus/cm2 scaffold. 
All patients included in this study received a bioresorb-
able scaffold of 3 mm in diameter and 18 mm in length. 
The implant is radiolucent but has two platinum markers 
of 244 μm at each end that allows for easy visualisation 
on CTA [9]. Both PLLA and PDLLA are fully resorbable 
[10].
Fig. 1  Flowchart of patients included in this analysis. From the 
overall ABSORB Cohort B cohort (n = 101), 35 patients underwent 
both coronary CTA and OCT analysis. Eight cases were non-analyz-
able. For this analysis 26 patients with both image modalities were 
included. CTA computed tomography angiography, TLR Target vessel 
revascularization, OCT Optical coherence tomography
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Coronary CTA Acquisition
Coronary CTA angiography was performed with different 
CT scanners: GE Lightspeed VCT 64-detector [10], Phil-
lips Brilliance 64-detector [4], Siemens Flash 256-detec-
tor [15], Phillip Brilliance ICT 256-detector [6]. Standard 
acquisition techniques were used, which included beta-
blockers in patients with heart rate >65  bpm, tube set-
tings depending on patient body mass index (80–140 kV), 
and axial scan protocols for patients with lower heart 
rates to reduce radiation doses, all at the discretion of the 
individual sites [11]. Images were reconstructed using 
thin slices (0.5–0.67  mm) and medium smooth recon-
struction filters in different phases. All data were stored 
on a DVD for core laboratory evaluation.
Coronary CTA analysis
Data from coronary CTA was analysed off-line by an 
independent Corelab (Cardialysis BV, Rotterdam, The 
Netherlands) using a validated cardiovascular analysis 
package (QAngioCT Research Edition version 3.0.14, 
Medis, Leiden, The Netherland). Vessel cross-sections 
were reconstructed at approximately 0.5  mm longitudi-
nal increments, using the platinum scaffold markers as 
landmarks. Automatic lumen segmentation of the ves-
sel lumen was performed; manual corrections using an 
attraction points tool was allowed. A window display set-
ting of level 750 Hounsfield units and width 250 Houns-
field units were used for the analysis, and was adjusted 
if necessary. In addition, gradient images were used to 
assist the detection of the luminal contour. The minimal 
lumen area (MLA) was determined for each scaffold. The 
non-scaffolded lumen area was assessed 5 mm proximal 
and distal to each marker. To evaluate the concordance in 
the axial distribution of the MLA, each scaffold of 18 mm 
length was divided into three segments. The position of 
the scaffold MLA was measured from the distal radio-
paque marker and compared from the distance obtained 
from OCT. Concordance was defined as localization of 
the MLA in the same scaffold segments (i.e., proximal, 
mid and distal). Additionally, to investigate the lumen 
contour tracing method at the level of the marker cross-
section, three strategies were compared based on the 
agreement with the OCT-derived lumen area. The marker 
was divided in three parts by 2 parallel lines. Afterward, 
the extrapolation of the luminal contour through the 
marker artefact was manually drawn tangential to the first 
line i.e., closest to the lumen (first strategy), to the cen-
tre of the marker (second strategy) and to the second line 
(third strategy). The gradient image visualization tool 
was used to identify the centre of the marker.
Optical coherence tomography analysis
OCT acquisitions were performed using three differ-
ent commercially available systems: the M2 and M3 
Time- Domain Systems and the C7XR Fourier-Domain 
System (LightLab Imaging, Westford, Massachusetts). 
OCT images were acquired at frame rates of 15.6, 20, and 
100 frames/s with pullback speeds of 2, 3, and 20 mm/s in 
the M2Time-Domain System,M3 Time- Domain System, 
and C7XR Fourier-Domain System (LightLab Imaging), 
respectively. All recordings were performed according to 
the recommended procedure for each OCT system [12]. 
The OCT measurements were performed with the QCU-
CMS software version 4.69 (Leiden University Medical 
Center, Leiden, The Netherlands) by the core laboratory 
(Cardialysis BV, Rotterdam, the Netherlands). The follow-
ing parameters were evaluated: MLA, lumen area at the 
proximal and distal marker cross-section, and the distance 
from the distal marker to the MLA. For the proximal and 
distal reference segments, the luminal area at the non-scaf-
folded region was measured at 5 mm from the proximal and 
distal radiopaque markers. Bifurcation segments in which 
the side branch occupied more than 45° of the cross-section 
were excluded in order to avoid tracing interpolation when 
quantifying the lumen [13]. In case the metallic marker of 
the scaffold could not be identified due to the wire shadow 
artefact or insufficient flush of blood, the cross-section and 
the associated proximal or distal edge cross-sections were 
not included in the analysis.
The primary objective was to assess the accuracy of 
coronary CTA for the measurement of in-scaffold minimal 
lumen area with OCT as a reference. The secondary objec-
tive was to validate the strategy of coronary CTA luminal 
contour tracing at the level of the radiopaque markers with 
matched OCT area as a reference.
Statistical analysis
Binary variables are presented as percentages and continu-
ous variables as mean and standard deviation or median 
and interquartile range, as appropriate. Continuous vari-
ables with normal distributions were compared using t test. 
The level of agreement between methods at the cross-sec-
tion level was determined using the Bland–Altman method 
and the Passing-Bablok regression analysis [14]. For the 
Bland–Altman method, data are given as plots showing 
the absolute difference between corresponding measure-
ments of both methods (y-axis) against the average of both 
methods (x-axis). Accuracy was defined as the mean dif-
ference between OCT and coronary CTA and precision as 
the standard deviation of the difference. The 95% limits of 
agreement were calculated as mean bias ± 1.96 × standard 
deviation. For the Passing-Bablok regression analysis, the 
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α and β coefficient assess for the systematic and propor-
tional differences. If 0 is in the confident interval (CI) of α, 
and 1 is in the CI of β, the two methods are comparable. If 
0 is not in the CI of α there is a systematic difference and if 
1 is not in the CI of β then there is a proportional difference 
between the two methods. Intra and inter-observer variabil-
ity were assessed using intra-class correlation coefficients. 
All statistical analyses were performed with SPSS software 
version 23.0 (IBM, Armonk, New York). This study was 
funded by Abbott Vascular.
Results
Overall, 35 patients with both OCT and coronary CTA 
evaluations were included in this analysis. Baseline clini-
cal and lesions characteristics are shown in Table  1. The 
mean age was 63.2 ± 9.0 years and 77% were male. The 
Left Anterior Descending artery was the most frequent 
treated vessel in 46% of the cases. Lesions were classified 
according to AHA/ACC as B1 and B2 in 90% of the cases. 
Images were acquired with a mean difference of 182 ± 19 
days. CTA images were acquired with a mean heart rate of 
53.8 ± 6.82  bpm. Coronary CTA quantitative analysis in 
the scaffold region was possible in 26 cases (76%) (Fig. 1). 
There were no systematic or proportional differences in 
minimum luminal area assessment between OCT and coro-
nary CTA (4.48 ± 1.57 mm2 OCT versus 4.04 ± 1.35 mm2 
coronary CTA, α coefficient −1.12 95% CI −4.78 to 0.66, 
β coefficient 1.12 95% CI 0.70 to 1.9)  respectively. Coro-
nary CTA underestimated luminal area by 9.8% in both 
scaffolded and non-scaffolded segments. In the scaffolded 
region, the accuracy and precision of coronary CTA at the 
MLA was 0.39 ± 1.0 mm2 (95% limits of agreements −1.71 
to 2.50 mm2). In addition, the analysis of 31 matched cross-
sections in the non-scaffolded segments at the proximal and 
distal edge showed similar level of agreement compared to 
the scaffolded region (accuracy 0.45 ± 0.70 mm2, limits of 
agreement −0.92 to 1.82 mm2, α coefficient −0.013 95% CI 
−0.9 to 0.86, β coefficient 0.93 95% CI 0.75–1.08) (Fig. 2). 
Concordance of axial in-scaffold MLA localization was 
observed in 77% of the cases (Case example Fig. 3). The 
intra-class correlation coefficient of in-scaffold MLA meas-
urements for inter-observer agreement was 0.98 (95% CI 
0.93–0.99; p < 0.001) and 0.98 (95% CI 0.94–0.99) for 
intra-observer agreement.
Luminal assessment at the level of the radiopaque 
marker
Forty cross sections at the level of the radiopaque marker 
were evaluated (16 were excluded due to impossibility to 
identify the marker using OCT (n = 13) and overlap with 
a metallic stent (n = 3)). When the luminal contour was 
traced across the centre of the radiopaque marker (i.e., 
second strategy) the coronary CTA-derived lumen area 
showed a mean difference of the 0.48 mm2 (limits of agree-
ments −1.55 to 2.51  mm2) with OCT-derived matched 
area as a reference. The inclusion in the luminal segmen-
tation of one-third (first strategy) and two-thirds (third 
strategy) showed a mean difference of 1.21 mm2 (limits of 
agreements −0.68 to 3.11 mm2), and −0.58  mm2 (limits 
of agreements −2.95 to 1.74  mm2), respectively (Fig.  4). 
Figure 5 shows the overall agreement in MLA and marker 
cross-section luminal areas between OCT and coronary 
CTA.
Discussion
The main findings of this analysis are (1) At 18 months, 
coronary CTA-derived in-scaffold minimal lumen area 
showed good agreement with OCT-derived minimal lumen 
area; (2) At the level of the marker with the blooming arte-
fact, luminal segmentation through the centre of the marker 
showed the best agreement with the matched OCT-derived 
area; and (3) There was similar agreement between lumi-
nal measurement at the scaffolded and non-scaffolded 
segments.
Non-invasive coronary CTA have demonstrated high 
accuracy for the evaluation of native coronary vessels 
Table 1  Baseline characteristics
Overall (n = 35)
Age (mean ± SD), years 63.2 ± 9.0
Male sex, n (%) 27 (77)
Diabetes mellitus, n (%) 2 (3)
Current smoker n (%) 9 (25)
Hyperlipidemia requiring medication, n (%) 27 (77)
Hypertension, n (%) 21 (60)
Prior PCTA, n (%) 7 (20)
Prior myocardial infarction, n (%) 10 (29)
Treated vessel
 Left anterior descending, n (%) 16 (46)
 Left circumflex, n (%) 8 (23)
 Right coronary artery, n (%) 11 (31)
AHA/ACC lesion classification
 A, n (%) 1 (3)
 B1, n (%) 17 (48)
 B2, n (%) 15 (42)
 C, n (%) 2 (6)
Mean reference vessel diameter, (mm) 2.53 ± 0.57
Minimum luminal diameter, (mm) 1.05 ± 0.29
Diameter stenosis, (%) 56 ± 13.7
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compared to invasive coronary angiography. In the land-
mark multicentre CORE-64 study, coronary CTA showed 
high diagnostic accuracy for the detection of coronary 
lesions with diameter stenosis ≥50% [15]. Moreover, a 
meta-analysis assessing the accuracy of coronary CTA 
to measure coronary luminal area at the cross-section 
level found an excellent agreement (mean difference of 
0.23 mm2, CI 95% −0.07 to 0.48) compared to IVUS [16]. 
In this study, coronary CTA underestimated in-scaffold 
MLA by 0.39  mm2 compared to OCT (4.48 ± 1.57  mm2 
OCT versus 4.04 ± 1.35 mm2 CTA). Similar agreement was 
observed in the non-scaffolded region (mean difference 
0.45 mm2, limits of agreement −0.92 to 1.82 mm2). These 
findings are comparable with previous reports comparing 
luminal areas derived from IVUS and coronary CTA in 
native coronary vessels [16]. 
Coronary CTA evaluation in segments treated with 
metallic stents is hampered by the presence of the metal; 
whereas the polymeric struts of the biodegradable scaf-
fold do not interfere with non-invasive luminal evaluation 
[17]. Moreover, high concordance in axial MLA localiza-
tion (77%) was observed. In three of the six cases with dis-
cordant MLA localization between modalities, the MLA 
derived from the OCT was at the level of the radiopaque 
marker. At this level, the blooming artefact from the radi-
opaque marker might have interfered with an appropriate 
luminal evaluation by coronary CTA; therefore, contribut-
ing to the relocation of the MLA.
The focal partial volume averaging and bean hardening 
artefacts at the scaffold marker cross-section makes coro-
nary luminal segmentation challenging. Two 244 micron 
platinum markers at each site of scaffold create a bloom-
ing artefact leading to an artificial increase in the size of 
the structure that precludes appropriate visualization of the 
lumen boundary. At the marker cross-section, we reported 
the agreement between three coronary CTA luminal seg-
mentation tracing strategies. The inclusion of the cen-
tre of the marker in the luminal area was associated with 
the higher accuracy (0.48 mm2, 95% limits of agreements 
−1.55 to 2.51  mm2). This is technically relevant, since 
Fig. 2  (Left side) Bland–Altman plots of the mean differences in 
luminal areas between optical coherence tomography CTA in scaf-
folded (top) and non-scaffolded segments (bottom). In the right side 
of the scatterplots with passing-Bablok analysis between modalities 
in both scaffolded (top) and non-scaffolded segments (bottom)
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automated luminal contour detection algorithms might 
recognized the blooming artefact of the marker with high 
Hounsfield units (mean 1435 ± 412 HU) as dense calcium 
and exclude it from the lumen creating a systematic under-
estimation of the luminal area at the marker cross-section. 
Therefore, manual correction of the luminal contour in 
needed at this level. The accuracy of in-scaffold quantita-
tive luminal analysis observed in this study supports the 
use of coronary CTA as the modality of choice for the fol-
low-up of patients treated with bioresorbable vascular scaf-
folds. Also, the validation of the tracing methods through 
the center of the radiopaque marker provides further guid-
ance for the quantitative segmentation of the lumen vessel.
To our knowledge this is the first study comparing 
coronary CTA in-scaffold luminal area dimensions with 
OCT. The small bias in the assessment of a clinically rel-
evant non-ambiguous parameter, such as MLA, supports 
the use of coronary CTA angiography as an alternative 
method to quantify non-invasively in-scaffold luminal 
area and to further processing using computational fluid 
dynamics [18]. Indeed, non-invasive coronary CTA angi-
ography have proven to the an accurate tool to assess 
endothelial shear stress and non-invasive fractional flow 
reserve [19, 20]. In the NXT Trial (Analysis of Coronary 
Blood Flow Using CT Angiography: Next Steps), coro-
nary CTA-derived fractional flow reserve demonstrated 
Fig. 3  Case example of an coronary CTA straight multiplanar 
reconstruction image and optical coherence tomography correlating 
matched luminal areas at the scaffold and non-scaffolded segments. 
Panels a, a′ and e, e′ show the vessel lumen at the non-scaffolded 
segments. Panels b, b′ and d, d′ show the cross-section at the level of 
the radiopaque markers, and panel c and c′ correspond to the MLA. 
The MLA with coronary CTA (c) was 3.4  mm2 and with 4.0  mm2 
with OCT (c′). The markers are shown with white arrows and a white 
stars identify the sidebranch. CTA computed tomography angiogra-
phy, MLA Minimal lumen area
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high per-patient sensitivity 86% (95% CI 77–92%) and 
specificity 79% (95% CI 72–84%) to identify myocardial 
ischemia compared to invasive FFR [20]. In addition, 
Bourantas et  al. have shown that coronary CTA-derived 
low shear stress correlates with coronary plaque progres-
sion in 3 years of follow up [21].
Fig. 4  a Cross-section at the level of the radiopaque marker with 
the blooming artefact (white arrows) and the coronary artery lumen 
(yellow arrow). b CT-gradient image at the same cross-section, the 
radiopaque marker (blue line, area of 2.5 mm2) is readily identified. 
c Three strategies evaluated to measure the agreement between coro-
nary CTA and OCT derived luminal areas (yellow double dash lines 
represents the position of the lumen with respect to the marker arte-
fact); the first strategy in red dash line included in the luminal area 
1.1 mm2 of the blooming artefact without crossing the centre of the 
marker; the second strategy in blue dash line included 2.3 mm2 of the 
blooming artefact and crossed the centre of the marker and the third 
strategy in black dash line included 3.2 mm2 of the blooming artefact 
and the centre of the marker. d Contour tracing methods with the best 
agreement (second strategy, blue line) with the OCT-derived matched 
lumen area. In the bottom, the three tracing strategies are plotted 
against the OCT-derived lumen area. CTA computed tomography 
angiography, OCT optical coherence tomography
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Limitations
The main limitation of this study in the inclusion of non-
complex, non-calcified lesion in which coronary CTA has 
proven to have higher accuracy; therefore, this finding 
should be confirmed in a more complex population [22]. 
Also, the low incidence of in-scaffold restenosis limits the 
conclusion of this analysis to patent scaffolds. Moreover, 
the 3  mm scaffold diameter included in this study might 
have facilitated the quantitative assessment The accuracy 
of coronary CTA to investigate the commercially available 
2.5 mm diameter scaffold is still unknown. Image acquisi-
tion was not performed at the same time; therefore, intro-
ducing a confounding factor. Nevertheless, the serial inva-
sive angiography analysis in this population reported stable 
luminal dimensions in the timeframe evaluated in this study 
(i.e., after 12 months) [1]. And finally, due to the limita-
tion in spatial resolution of coronary CTA coronary cross-
section matched by OCT and coronary CTA may not be 
exactly identical.
Conclusion
Compared with OCT, coronary CTA appears to be accu-
rate for the estimation of in-scaffold minimal lumen area 
18-month post-implantation, with no difference compared 
to the non-scaffolded region.
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